A Pilot, Safety, Feasibility and Efficacy Trial of Hemoperfusion during Continuous Renal Replacement Therapy in Critically Ill Patients with Combined Liver and Kidney Failure

Not Applicable

• Conditions: iver failure; Kidney failure; Liver failure; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon; Renal and Urogenital - Other renal and urogenital disorders

• Registration Number: ACTRN12622001040752
• Lead Sponsor: Austin Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-07-26
• Last Update Posted: 9 August 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Liver failure and severe acute kidney injury requiring continuous renal replacement therapy
Expected to continue to receive continuous renal replacement therapy for equal to or greater than 48 hours from the time of enrolment

Exclusion Criteria

Suspected or confirmed pregnancy
Do not resuscitate (DNR) order in place
Do not intubate (DNI) order in place
Death is deemed inevitable or imminent during this admission, and either the attending physician, patient or substitute decision-maker is not committed to active treatment
Known human immunodeficiency virus (HIV) infection
Another illness is present that in the investigator’s judgement, will substantially increase the risk associated with the participants participant in the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified